Q3 2026 Financial Results & Corporate Update



Leading the Next Era of Precision Medicine

November 10, 2026

AGENDA

01 Opening Remarks
Troy Wilson, Ph.D., J.D.
President & Chief Executive Officer

02 Commercial Progress
Brian Powl
Chief Commercial Officer

03 Clinical Development Updates
Mollie Leoni, M.D.
Chief Medical Officer

04 Financial Update
Jennifer Fulk
Chief Financial Officer

05 Closing Remarks
Troy Wilson, Ph.D., J.D.
President & Chief Executive Officer

FORWARD-LOOKING STATEMENTS

This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The words "believe," "may," "should," "will," "estimate," "plan," "continue," "anticipate," "intend," "expect," "potential," "vision" and similar expressions (including the negative thereof) are intended to identify forward-looking statements. Such statements include, but are not limited to, statements regarding the future operations, financial results and financial condition of Kura Oncology, Inc. ("Kura," "Kura Oncology," "we," "us" or "our"); expectations regarding clinical trial initiation, enrollment and progress; the expected timing and presentation or publication of clinical data; the potential of ziftomenib to address up to 50% of patients with acute myeloid leukemia ("AML"); the potential of ziftomenib/FLT3-inhibitor combinations to broaden ziftomenib's impact for AML patients; expectations regarding the expanded adoption of KOMZIFTI® in relapsed/refractory NPM1-mutated AML; the potential of the KOMET-017 program to support a frontline AML therapy; darlifarnib's potential registrational path; expectations regarding regulatory approvals and development in additional indications, including the potential of the planned clinical trial of darlifarnib in HRAS-mutant salivary gland cancer to support full approval and the timing of approval relative to combination submissions; the potential to advance darlifarnib combinations in renal cell cancer and pancreatic ductal adenocarcinoma and plans to evaluate additional darlifarnib combinations; potential funding through the strategic financing with Oberland Capital and the anticipated benefits of such financing; anticipated cash runway and collaboration payments; and expectations regarding our collaboration with Kyowa Kirin. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Factors that contribute to the uncertain nature of the forward-looking statements include: risks associated with market competition, market acceptance and commercialization of KOMZIFTI; risks associated with the conduct of preclinical studies and clinical trials; the risk that we may not obtain access to compounds we seek to evaluate in combination with our product candidates; the potential for the U.S. Food and Drug Administration ("FDA") to disagree with our interpretation of clinical trial data, to require additional clinical trials or to require modifications to ongoing clinical trials and the risk that FDA alignment on a study design may not result in approval; potential delays in the commencement, enrollment, completion or analysis of clinical testing, reporting of data or initiation of planned studies; significant issues regarding clinical trial design or execution that could result in increased costs and delays or limit our ability to obtain regulatory approval; the risk that our product candidates or additional indications may not receive regulatory approval; the potential for KOMZIFTI or our product candidates to have unexpected adverse side effects; risks that early clinical results, including preliminary response and durability data, may not be confirmed in larger or later-stage trials; the risk that the anticipated market opportunity for KOMZIFTI or our product candidates may differ from our current expectations; the risk that we may not be able to obtain additional financing; the risk that anticipated financing or milestone payments may be delayed or unavailable; risks associated with debt obligations and equity dilution; and the risk that our collaboration with Kyowa Kirin may not be successful. Additional risks and uncertainties may emerge from time to time, and it is not possible for Kura's management to predict all risk factors and uncertainties.

All forward-looking statements contained in this presentation speak only as of the date on which they were made. Other risks and uncertainties affecting us are described more fully in our filings with the Securities and Exchange Commission ("SEC"). We undertake no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

This presentation may also contain statistical, preclinical and clinical data obtained from and prepared by third parties. The recipient is cautioned not to give undue weight to such disclosures. Neither Kura nor any other person makes any representation as to the accuracy or completeness of such data or undertakes any obligation to update such data after the date of this presentation.

TWO PRECISION ONCOLOGY FRANCHISES

ZIFTOMENIB


- **1st precision medicine product with differentiated clinical profile**
- **Strong commercial launch** and **sustained leadership** in R/R *NPM1*-m AML
- Advancing ziftomenib to address **up to 50% of AML patients**
- **Eight presentations at ASH 2026**, including **4 orals** and two FLT3 inhibitor combination studies

DARLIFARNIB

- **2nd precision medicine product** on a **potential registrational path**
- FDA alignment on 40-patient, single-arm, monotherapy trial in *HRAS*-m SGC for **potential full approval**
- **Combinations** with cabozantinib (RCC) and daraxonrasib (PDAC) **advancing**
- **Multiple milestones** and clinical updates anticipated in 2027

DIFFERENTIATED PROFILE SUPPORTS ADOPTION AND GROWTH

KOMZIFTI is indicated for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with a susceptible nucleophosmin 1 (*NPM1*) mutation who have no satisfactory alternative treatment options.



Please see additional Important Safety Information and full Prescribing Information, including Boxed Warning.

KOMZIFTI: STRONG GROWTH + CONTINUED LEADERSHIP

First and only once-daily targeted therapy for adults with R/R *NPM1*-m AML



~150
new patient starts

+30% over Q2

420+
total prescriptions

+65% over Q2

~170
accounts

+40% over Q2

~50%
of patients received KOMZIFTI in combination with other approved agents*

$13.9M net product revenue


+53% over Q2

*According to claims data. KOMZIFTI is only promoted on its FDA-approved indication.

Please see additional Important Safety Information and full Prescribing Information, including Boxed Warning.

FLT3 INHIBITOR COMBINATIONS COULD BROADEN ZIFTOMENIB'S POTENTIAL IMPACT FOR AML PATIENTS

Nearly one-third of patients with AML and nearly half of all patients with an NPM1 mutation have a FLT3 co-mutation.



ASH 2026: Two Oral Presentations on FLT3 Inhibitor Combinations

1

KOMET-008

Ziftomenib combined with **gilteritinib** for R/R *NPM1* and *FLT3* co-mutated AML patients

2

KOMET-007

Ziftomenib combined with **quizartinib** and intensive induction (7+3) for newly diagnosed *NPM1*-m and *FLT3*-ITD+ AML patients

* MEIS-high subtypes including *FLT3, DNMT3A, IDH1/2, and NUP98.*

ASH 2026 SHOWCASES BREADTH OF ZIFTOMENIB DEVELOPMENT

ORALS

FLT3

Dec 12 - 10:45 a.m. CST
KOMET-008
Ziftomenib + gilteritinib
R/R *NPM1/FLT3* co-mutated AML

Dec 14 – 3:00 p.m. CST
KOMET-007
Ziftomenib + quizartinib + 7+3
Newly diagnosed *NPM1/FLT3* co-mutated AML

Pediatric

Dec 13 - 5:45 p.m. CST
PedAL
Ziftomenib + fludarabine + cytarabine
R/R acute leukemia

POSTERS

Ven/Aza

Dec 14 – 6:00 p.m. CST
KOMET-007: ziftomenib + ven/aza
Newly diagnosed *NMP1* AML

Other AML subtypes

Dec 14 – 6:00 p.m. CST
MEIS 1-associated genomic subtypes

BROAD DEVELOPMENT PROGRAM EVALUATING ZIFTOMENIB ACROSS THE AML TREATMENT CONTINUUM

RELAPSED / REFRACTORY

IC or NIC Therapy or Tolerable Therapy

Transplant/ No Transplant

Targeted Therapy in *FLT3*-m, *IDH1*/2-m and/or *NPM1*-m

Non-Intensive Therapy/ Palliative Care

komet ACUTE LEUKEMIAS

KOMET-001
NPM1-m AML
Non-*NPM1*-m / Non-*KMT2A*-r AML

KOMET-007
Zifto + Ven/Aza

KOMET-008
Zifto + FLAG-IDA
Zifto + LDAC
Zifto + gilt

1L TREATABLE

IC or NIC Therapy

Transplant/ No Transplant

Post-Transplant/ Consolidation Maintenance

komet ACUTE LEUKEMIAS

KOMET-007
Zifto + Ven/Aza
Zifto + 7+3
Zifto + 7+3 + quiz

KOMET-017-IC
Zifto + 7+3
Placebo + 7+3

KOMET-017-NIC
Zifto + Ven/Aza
Placebo + Ven/Aza

Investigator/Company-Sponsored Studies Across Adult and Pediatric Hematologic Malignancies

DARLIFARNIB

Second Precision Oncology Product on a Potential Registrational Path

- Aligned with FDA on a **single-arm monotherapy registrational study** evaluating darlifarnib in patients with *HRAS*-mutant salivary gland cancer to support **potential full approval**
- Total sample size ~ 40 patients
- Initiation planned for 1H 2027
- Rationale based on KOL demand and confirmed responses observed with darlifarnib
- Potential FDA approval expected ahead of combination submissions and could provide clinical, regulatory and commercial foundation

LOOKING AHEAD: DARLIFARNIB MILESTONES IN 2027

1H

- Complete enrollment in Phase 1b of darlifarnib + cabozantinib in advanced cabozantinib-naïve RCC
- Initiate ~40-patient Phase 2 registrational study of darlifarnib in *HRAS*-m salivary gland cancer
- Initiate Phase 1 of darlifarnib + daraxonrasib in metastatic PDAC

2H

- Report preliminary data from Phase 1b of darlifarnib + cabozantinib in advanced RCC
- Report preliminary data from Phase 1a of darlifarnib + daraxonrasib in PDAC
- Evaluate additional darlifarnib combinations for potential clinical studies

FINANCIAL HIGHLIGHTS AND OUTLOOK

Capitalized to support KOMZIFTI commercial launch and pipeline advancement

- **$492.1 million** in cash, cash equivalents and short-term investments as of September 30, 2026
- In addition to existing cash resources, Kura anticipates **$180 million** in milestone payments from Kyowa Kirin
- Access up to **$300 million** in potential funding under Oberland agreement
- Based on current operating plan, Kura expects these cash resources to support operations beyond the initial topline results from the pivotal Phase 3 KOMET-017 study of ziftomenib, anticipated in 2028

CORPORATE PRIORITIES FOR THE NEXT STAGE OF GROWTH

- **Expand KOMZIFTI adoption** in R/R *NPM1*-m AML
- **Deliver the ASH ziftomenib data set**, led by the first *FLT3* combination updates
- **Execute KOMET-017** to support a new standard-of-care in frontline AML
- **Initiate the darlifarnib registrational study** in *HRAS*-mutant salivary gland cancer
- **Advance darlifarnib combinations** in RCC and PDAC
- **Maintain capital flexibility** beyond the first KOMET-017 topline readout

ON A PERSONAL NOTE . . .





Question & Answer

THANK YOU



Leading the Next Era of Precision Medicine